Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 2/20 | 0.62 |
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.53 |
| ▸ | AKT1 | P31749 | 3/20 | 0.50 |
| ▸ | LIMK2 | P53671 | 4/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.47 |
| ▸ | PRKACA | P17612 | 2/20 | 0.47 |
| ▸ | PRKACG | P22612 | 2/20 | 0.47 |
| ▸ | PRKACB | P22694 | 2/20 | 0.47 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.47 |
| ▸ | PRKCH | P24723 | 1/20 | 0.47 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.47 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1046530 | 0.90 | JAK3 (0.62) | JAK3LRRK2AKT1 | |
| SCHEMBL1049422 | 0.90 | JAK3 (0.60) | JAK3LRRK2AKT1LIMK2 | |
| SCHEMBL1049598 | 0.86 | LRRK2 (0.51) | JAK3LRRK2AKT1LIMK2ROCK2 | |
| SCHEMBL1045971 | 0.84 | JAK3 (0.86) | JAK3 | |
| SCHEMBL1049842 | 0.81 | LIMK2 (0.51) | JAK3LRRK2AKT1LIMK2 | |
| SCHEMBL1049255 | 0.79 | JAK3 (0.60) | JAK3LRRK2AKT1 | |
| SCHEMBL323537 | 0.79 | JAK3 (0.89) | JAK3 | |
| SCHEMBL1050100 | 0.79 | JAK3 (0.57) | JAK3AKT1LIMK2 | |
| SCHEMBL1050757 | 0.78 | LIMK2 (0.51) | JAK3AKT1LIMK2ROCK2PRKACA | |
| SCHEMBL1050166 | 0.77 | AKT1 (0.52) | JAK3AKT1LIMK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2451813-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | Leo Pharma A/S (DK) | 2012-05-16 | — | — | EP | claimed |
| WO-2011003418-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2011-01-13 | — | — | WO | claimed |
| US-9346809-B2 | Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors | LEO PHARMA A/S (DK) | 2016-05-24 | — | — | US | disclosed |
| US-9346809-B2 | Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors | LEO PHARMA A/S (DK) | 2016-05-24 | — | — | US | disclosed |
| US-9346809-B2 | Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors | LEO PHARMA A/S (DK) | 2016-05-24 | — | — | US | disclosed |
| US-20120178740-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2012-07-12 | — | — | US | disclosed |
| US-20120178740-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2012-07-12 | — | — | US | disclosed |
| US-20120178740-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2012-07-12 | — | — | US | disclosed |
| EP-2451813-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | Leo Pharma A/S (DK) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011003418-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011003418-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178740-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | JAK1, JAK2, JAK3 | JAK3 3/4885LRRK2 261/4885AKT1 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.